Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679544 | 0.95 | PIM1 (0.46) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679542 | 0.95 | PIM1 (0.46) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679543 | 0.95 | PIM1 (0.46) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679831 | 0.93 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL678088 | 0.93 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679833 | 0.93 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679788 | 0.93 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679773 | 0.93 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL679032 | 0.93 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 | |
| SCHEMBL678089 | 0.93 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214325-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2005-11-09 | — | — | EP | claimed |
| US-20210283051-A1 | VE-PTP INHIBITION IN GLAUCOMA | Mannin Research, Inc. (CA) | 2021-09-16 | — | — | US | disclosed |
| EP-3820458-A1 | VE-PTP INHIBITION IN GLAUCOMA | Quaggin, Susan (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020012444-A1 | VE-PTP INHIBITION IN GLAUCOMA | QUAGGIN SUSAN (US) | 2020-01-16 | — | — | WO | disclosed |
| WO-2019016826-A1 | NOVEL 5-[4-(2-BIPHENYL-4-YL-2-OXO-ETHOXY)-BENZYLIDENE]-THIAZOLIDINE-2,4-DIONES, THEIR SYNTHESIS AND USES THEREOF | GURU GHASIDAS VISHWAVIDYALAYA (A CENTRAL UNIVERSITY) (IN) | 2019-01-24 | — | — | WO | disclosed |
| WO-2010082212-A2 | N-BIPHENYLACYL THIAZOLIDINE-2,4-DIONE DERIVATIVES, THEIR SYNTHESIS AND USES | ELDER PHARMACEUTICALS LTD (IN) | 2010-07-22 | — | — | WO | disclosed |
| US-20090204336-A1 | PDZ-Domain Modulators | FORSCHUNGSVERBUND BERLIN E. V. (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-1893199-A2 | PDZ-DOMAIN MODULATORS | Forschungsverbund Berlin e.V. (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006119736-A2 | PDZ-DOMAIN MODULATORS | COMBINATURE BIOPHARM AG (DE) | 2006-11-16 | — | — | WO | disclosed |
| US-6353011-B1 | 1,2-dithiolane derivatives | UNIVERSITY OF MISSISSIPPI | 2002-03-05 | — | — | US | disclosed |
| US-6204288-B1 | TREATING DISEASES MEDIATED BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; ANTI-DIABETIC AGENTS AND REGULATION OF LIPID METABOLISM | THE UNIVERSITY OF MISSISSIPPI | 2001-03-20 | — | — | US | disclosed |
| US-6127394-A | TREATMENT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS MEDIATED DISEASE LIKE CARDIOVASCULAR DISEASES, ENDOCRINE DISEASES, INFLAMMATORY DISEASES, TUMOR AND NON-MALIGNANT PROLIFERATIVE DISEASES, NEURO-PSYCHIATRIC DISORDERS | THE UNIVERSITY OF MISSISSIPPI (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000053601-A1 | 1,2-DITHIOLANE DERIVATIVES | THE UNIVERSITY OF MISSISSIPPI (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090204336-A1 | PDZ-Domain Modulators | PDLIM5, DVL1, PSD | PIM1 1210/4885PIM2 913/4885IGF1R 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.